{"id":"guselkumab-subcutaneous","safety":{"commonSideEffects":[{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2364648","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Guselkumab binds to the p19 subunit of IL-23, a key cytokine involved in the differentiation and activation of pathogenic T cells in inflammatory skin and immune-mediated diseases. By inhibiting IL-23 signaling, the drug suppresses the Th17 cell response and downstream inflammatory cascades, reducing skin inflammation and systemic immune activation. This mechanism is particularly effective in psoriasis and other IL-23-driven inflammatory conditions.","oneSentence":"Guselkumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) signaling to reduce inflammatory immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:43.188Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT05242484","phase":"PHASE2","title":"A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-09-19","conditions":"Colitis, Ulcerative","enrollment":577},{"nctId":"NCT07310095","phase":"PHASE4","title":"A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)","status":"RECRUITING","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2025-12-30","conditions":"Crohn Disease","enrollment":78},{"nctId":"NCT03466411","phase":"PHASE2, PHASE3","title":"A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-13","conditions":"Crohn's Disease","enrollment":1409},{"nctId":"NCT05528510","phase":"PHASE3","title":"A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-09-13","conditions":"Colitis, Ulcerative","enrollment":418},{"nctId":"NCT05071664","phase":"PHASE2","title":"A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-25","conditions":"Arthritis, Psoriatic","enrollment":91},{"nctId":"NCT06408935","phase":"PHASE3","title":"Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients","status":"RECRUITING","sponsor":"Janssen-Cilag Ltd.","startDate":"2024-04-17","conditions":"Crohn's Disease","enrollment":112},{"nctId":"NCT05083182","phase":"PHASE3","title":"A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-08-30","conditions":"Arthritis, Juvenile","enrollment":50},{"nctId":"NCT06260163","phase":"PHASE3","title":"A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-01-19","conditions":"Colitis, Ulcerative","enrollment":112},{"nctId":"NCT04929210","phase":"PHASE4","title":"A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-30","conditions":"Arthritis, Psoriatic","enrollment":411},{"nctId":"NCT07141004","phase":"PHASE4","title":"A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)","status":"RECRUITING","sponsor":"Johnson & Johnson Private Limited","startDate":"2025-08-12","conditions":"Arthritis, Psoriatic","enrollment":100},{"nctId":"NCT06663332","phase":"PHASE3","title":"A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-29","conditions":"Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic","enrollment":196},{"nctId":"NCT04397263","phase":"PHASE3","title":"A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2020-06-10","conditions":"Crohns Disease","enrollment":38},{"nctId":"NCT07430319","phase":"","title":"Real-Life Evaluation of Guselkumab Dosing Interval Adjustments","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2025-10-16","conditions":"Psoriasis","enrollment":100},{"nctId":"NCT05197049","phase":"PHASE3","title":"A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-01-19","conditions":"Crohn Disease","enrollment":350},{"nctId":"NCT05242471","phase":"PHASE2","title":"A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-22","conditions":"Crohn's Disease","enrollment":703},{"nctId":"NCT06651489","phase":"PHASE2","title":"Efficacy of Guselkumab in Treating Hailey Hailey Disease","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-03-13","conditions":"Hailey Hailey Disease","enrollment":10},{"nctId":"NCT07246460","phase":"","title":"Ultrasound and Proteomics for Guselkumab Response Assessment in Crohn's Disease (UPGRADE).","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2025-10-31","conditions":"Crohn's Disease of Both Small and Large Intestine","enrollment":90},{"nctId":"NCT05669833","phase":"PHASE3","title":"Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-07-14","conditions":"Psoriatic Arthritis","enrollment":63},{"nctId":"NCT05272150","phase":"PHASE3","title":"Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-13","conditions":"Plaque Psoriasis, Scalp Psoriasis","enrollment":213},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT04683029","phase":"PHASE2","title":"A Study of Guselkumab in Participants With Systemic Sclerosis","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-02-24","conditions":"Scleroderma, Systemic","enrollment":56},{"nctId":"NCT06039189","phase":"PHASE3","title":"Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-08-24","conditions":"Moderate Plaque Psoriasis","enrollment":338},{"nctId":"NCT04633447","phase":"PHASE2","title":"A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-12-10","conditions":"Giant Cell Arteritis","enrollment":53},{"nctId":"NCT04394936","phase":"NA","title":"An Explorative Psoriasis Biomarker Study","status":"TERMINATED","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2020-09-01","conditions":"Psoriasis Vulgaris","enrollment":37},{"nctId":"NCT05004727","phase":"PHASE4","title":"Multi-Center PAMPA Study","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-02-16","conditions":"Psoriasis","enrollment":176},{"nctId":"NCT06916390","phase":"PHASE4","title":"GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis","status":"NOT_YET_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2025-09-30","conditions":"Pouchitis","enrollment":20},{"nctId":"NCT05125679","phase":"PHASE4","title":"Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis","status":"TERMINATED","sponsor":"Janssen-Cilag Ltd.","startDate":"2021-11-23","conditions":"Psoriasis","enrollment":15},{"nctId":"NCT04376827","phase":"PHASE2","title":"A Study of Guselkumab in Participants With Active Lupus Nephritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-15","conditions":"Lupus Nephritis","enrollment":33},{"nctId":"NCT05270733","phase":"PHASE4","title":"Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics","status":"RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2022-11-10","conditions":"Psoriasis","enrollment":56},{"nctId":"NCT04533737","phase":"PHASE4","title":"Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab","status":"TERMINATED","sponsor":"LEO Pharma","startDate":"2020-12-17","conditions":"Plaque Psoriasis, Psoriasis Vulgaris, Psoriasis","enrollment":113},{"nctId":"NCT02319759","phase":"PHASE2","title":"Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-03-27","conditions":"Psoriatic Arthritis","enrollment":149},{"nctId":"NCT04030533","phase":"PHASE1","title":"Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-29","conditions":"Healthy","enrollment":60},{"nctId":"NCT04147338","phase":"PHASE1","title":"A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-10-30","conditions":"Healthy","enrollment":440},{"nctId":"NCT03649971","phase":"PHASE1","title":"A Study of Guselkumab in Participants With Familial Adenomatous Polyposis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-19","conditions":"Adenomatous Polyposis Coli","enrollment":77},{"nctId":"NCT03796858","phase":"PHASE3","title":"A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2019-03-22","conditions":"Arthritis, Psoriatic","enrollment":285},{"nctId":"NCT04704843","phase":"PHASE1","title":"A Study of Guselkumab in Adult Participants With Celiac Disease","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2021-06-17","conditions":"Celiac Disease","enrollment":""},{"nctId":"NCT04080648","phase":"PHASE4","title":"Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2018-06-27","conditions":"Psoriasis Vulgaris","enrollment":79},{"nctId":"NCT04736966","phase":"PHASE1","title":"Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2021-03-03","conditions":"Alcoholic Liver Disease","enrollment":13},{"nctId":"NCT04061395","phase":"PHASE2","title":"Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study.","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2019-10-01","conditions":"Hidradenitis Suppurativa","enrollment":20},{"nctId":"NCT03662542","phase":"PHASE2","title":"A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-20","conditions":"Colitis, Ulcerative","enrollment":214},{"nctId":"NCT04914429","phase":"PHASE4","title":"A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-25","conditions":"Psoriasis","enrollment":327},{"nctId":"NCT03158285","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-07-12","conditions":"Arthritis, Psoriatic","enrollment":741},{"nctId":"NCT03998683","phase":"PHASE3","title":"A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2019-09-03","conditions":"Psoriasis","enrollment":117},{"nctId":"NCT02207231","phase":"PHASE3","title":"A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-11-26","conditions":"Psoriasis","enrollment":837},{"nctId":"NCT02207244","phase":"PHASE3","title":"A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-11-03","conditions":"Psoriasis","enrollment":992},{"nctId":"NCT03162796","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-08-24","conditions":"Arthritis, Psoriatic","enrollment":383},{"nctId":"NCT03573323","phase":"PHASE4","title":"A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-11-09","conditions":"Plaque Psoriasis","enrollment":1027},{"nctId":"NCT04084665","phase":"EARLY_PHASE1","title":"Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab.","status":"WITHDRAWN","sponsor":"Rockefeller University","startDate":"2020-06-01","conditions":"Hidradenitis Suppurativa","enrollment":""},{"nctId":"NCT02325219","phase":"PHASE3","title":"An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2014-12-19","conditions":"Psoriasis","enrollment":192},{"nctId":"NCT01866007","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-05-09","conditions":"Healthy","enrollment":141},{"nctId":"NCT02397382","phase":"PHASE1","title":"Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-06-18","conditions":"Psoriasis","enrollment":16},{"nctId":"NCT02203032","phase":"PHASE3","title":"A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-10-07","conditions":"Psoriasis","enrollment":872},{"nctId":"NCT00925574","phase":"PHASE1","title":"A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2009-06-04","conditions":"Psoriasis","enrollment":71},{"nctId":"NCT01484587","phase":"PHASE1","title":"A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2011-08-22","conditions":"Psoriasis","enrollment":24},{"nctId":"NCT01483599","phase":"PHASE2","title":"A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Janssen Inc.","startDate":"2011-11-10","conditions":"Psoriasis","enrollment":293},{"nctId":"NCT01645280","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-08","conditions":"Arthritis, Rheumatoid","enrollment":274},{"nctId":"NCT01845987","phase":"PHASE2","title":"A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2013-06","conditions":"Palmoplantaris Pustulosis","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":64,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CNTO1959","TREMFYA"],"phase":"phase_3","status":"active","brandName":"Guselkumab Subcutaneous","genericName":"Guselkumab Subcutaneous","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Guselkumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) signaling to reduce inflammatory immune responses. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis, Crohn's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}